Herceptin therapy in pregnancy: continuation of pregnancy in the presence of anhydramnios.
Warraich
Q
Q
Department of Obstetrics and Gynaecology, Aberdeen Maternity Hospital, Aberdeen, UK. qwarraich@btinternet.com
Smith
N
N
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000188:drug therapy*; D002585:Cesarean Section; D003131:Combined Modality Therapy; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008168:Lung / Q000002:abnormalities; D016104:Oligohydramnios / Q000139:chemically induced*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D001261:Pulmonary Atelectasis / Q000139:chemically induced; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab